To ex­pand its oral and top­i­cal dosage op­tions, Catal­ent will put $10M in­to mi­croniza­tion

In 2021, it seemed like every two weeks, CD­MO gi­ant Catal­ent would re­lease some sort of im­por­tant news. If there was any ques­tion of whether the com­pa­ny could keep up the pace this year, those con­cerns were quelled al­most im­me­di­ate­ly, when its col­or­ful, out­spo­ken, long­time CEO John Chimin­s­ki an­nounced that he would step down lat­er this year af­ter 12 years.

And in four weeks, the com­pa­ny has an­nounced four deals. The lat­est: Catal­ent will pump $10 mil­lion in­to ex­pan­sions at its Malvern, PA and Dart­ford, UK sites to ex­pand the large-scale iso­la­tor units, in an ef­fort to im­prove con­tain­ment ca­pa­bil­i­ties for the mi­croniza­tion of high­ly-po­tent drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER